Search Results 271-280 of 3955 for < yeotop3 쩜 com > 신창동오피☣신창동건마♃신창동키스방ⅵ신창동풀싸롱✦신창동오피➞신창동OP❖신창동립카페
About this study. The study is a multicenter, open label Phase I/II trial. 1. Establish the MTD of fractionated doses of Lintuzumab-Ac225 in combination ...
Subjects will receive dabrafenib 150 mg twice daily (BID) in monotherapy treatment and dabrafenib 150 mg bid and trametinib 2 mg once daily in combination ...
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...
About this study. The purpose of this study is to utilize neuECG, a new method to directly and non-invasively record skin sympathetic nerve activity (SKNA) ...
Dr. Miller's lab studies the class A cholecystokinin receptor and the class B secretin receptor, with a goal of advancing the development of receptor-active ...
A Phase 3 Study to Examine the Effectiveness, Safety and Tolerability of APL-130277 for the Acute Treatment of Motor Fluctuation Episodes in Patients with ...
About this study. The purpose of this study is to use the candidate gene approach to find the cause of the neuromuscular disease, determine mechanisms by ...
About this study. The purpose of this study is to evaluate a highly innovative project evaluating the feasibility of patient-centered home care (PCHC) as a ...
The purpose of this study is to evaluate the safety and tolerability of APG-2575 as well as dose escalation and dose expansion stages. Participation eligibility.
Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation can make a difference in the future of healthcare. Give now to support Mayo Clinic's research.